Nektar Therapeutics dropped 8.6% despite raising substantial capital and reporting positive clinical data. The biotech company completed two equity offerings…
Read More
Asian Startups Raised $66 Million in One Week as Climate Finance, Robotics, and Enterprise AI Attract Surging Investor Confidence
Asian startups raised over $66 million in Week 19, spanning home services, climate finance, semiconductors, robotics, and enterprise AI. Indian…
Read More
Santhera Pharmaceuticals, AOTI, Poolbeg Pharma, Solvonis Therapeutics, IBT – Health and Biotech Week in Review
About Stephen Gunnion Stephen Gunnion is a senior financial journalist and broadcaster at Proactive Investors. He has more than 25…
Read More
Germany’s mbiomics brings Series A to €30 million to scale microbiome therapeutics for chronic diseases
mbiomics, a Bavaria-based BioTech startup advancing scalable microbiome-based therapeutics for severe and chronic diseases, has announced the third closing of…
Read More
Oruka Therapeutics, Inc. Prices Upsized Public Offering of 9.66 Million Shares at $72.50 Per Share
MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focapplyd on…
Read More
Why Nektar Therapeutics (NKTR) Is Down 8.6% After Raising Capital And Reporting New Alopecia Data
Nektar Therapeutics recently completed a follow-on equity offering of about US$325.00 million and later closed an underwritten public offering totaling…
Read More
STORM Therapeutics raises €47.5 million Series C to harness the power of RNA modification to treat cancer
STORM Therapeutics (STORM), a Cambridge-based BioTech company tarreceiveing RNA modifications to reprogram cells and develop novel cancer therapies, today announced…
Read More
Heron Therapeutics stock faces renewed scrutiny amid pipeline delays and cash burn concerns in 2026
Heron Therapeutics (ISIN: US4277461020), the Nasdaq-listed biotech focutilized on oncology and supportive care, grapples with funding challenges. German-speaking investors should…
Read More
Ternary Therapeutics tarreceives “undruggable” proteins with AI-designed molecular glues, raising €4.1 million
London-based BioTech startup Ternary Therapeutics has raised €4.1 million (£3.6 million) in Seed funding to scale an AI platform designed…
Read More
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its…
Read More
